Intraductal	O
cisplatin	O
treatment	O
in	O
a	O
BRCA	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
mouse	B-OG
model	O
attenuates	O
tumor	B-DS
development	O
but	O
leads	O
to	O
systemic	O
tumors	B-DS
in	O
aged	O
female	O
mice	B-OG

BRCA	B-GP
deficiency	O
predisposes	O
to	O
the	O
development	O
of	O
invasive	B-DS
breast	I-DS
cancer	I-DS
.	O

In	O
BRCA	B-GP
mutation	O
carriers	O
this	O
risk	O
can	O
increase	O
up	O
to	O
80	O
%.	O

Currently	O
,	O
bilateral	O
prophylactic	O
mastectomy	O
and	O
prophylactic	O
bilateral	O
salpingo	O
-	O
oophorectomy	O
are	O
the	O
only	O
preventive	O
,	O
albeit	O
radical	O
invasive	O
strategies	O
to	O
prevent	O
breast	B-DS
cancer	I-DS
in	O
BRCA	B-GP
mutation	O
carriers	O
.	O

An	O
alternative	O
non	O
-	O
invasive	O
way	O
to	O
prevent	O
BRCA1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
may	O
be	O
local	O
prophylactic	O
treatment	O
via	O
the	O
nipple	O
.	O

Using	O
a	O
non	O
-	O
invasive	O
intraductal	O
(	O
ID	O
)	O
preclinical	O
intervention	O
strategy	O
,	O
we	O
explored	O
the	O
use	O
of	O
combined	O
cisplatin	O
and	O
poly	B-GP
(	I-GP
ADP	I-GP
)-	I-GP
ribose	I-GP
polymerase	I-GP
1	I-GP
(	O
PARP1	B-GP
)	O
inhibition	O
to	O
prevent	O
the	O
development	O
of	O
hereditary	B-DS
breast	I-DS
cancer	I-DS
.	O

We	O
show	O
that	O
ID	O
cisplatin	O
and	O
PARP	B-GP
-	O
inhibition	O
can	O
successfully	O
ablate	O
mammary	O
epithelial	O
cells	O
,	O
and	O
this	O
approach	O
attenuated	O
tumor	B-DS
onset	O
in	O
a	O
mouse	B-OG
model	O
of	O
Brca1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
from	O
153	O
to	O
239	O
days	O
.	O

Long	O
-	O
term	O
carcinogenicity	O
studies	O
in	O
150	O
syngeneic	O
wild	O
-	O
type	O
mice	B-OG
demonstrated	O
that	O
tumor	B-DS
incidence	O
was	O
increased	O
in	O
the	O
ID	O
treated	O
mammary	O
glands	O
by	O
6	O
.	O
3	O
%	O
due	O
to	O
systemic	O
exposure	O
to	O
cisplatin	O
.	O

Although	O
this	O
was	O
only	O
evident	O
in	O
aged	O
mice	B-OG
(	O
median	O
age	O
=	O
649	O
days	O
),	O
we	O
conclude	O
that	O
ID	O
cisplatin	O
treatment	O
only	O
presents	O
a	O
safe	O
and	O
feasible	O
local	O
prevention	O
option	O
if	O
systemic	O
exposure	O
to	O
the	O
chemotherapy	O
used	O
can	O
be	O
avoided	O
.	O

INTRODUCTION	O

Breast	B-DS
cancer	I-DS
risk	O
increases	O
dramatically	O
in	O
women	O
carrying	O
mutations	O
in	O
a	O
breast	B-DS
cancer	I-DS
susceptibility	O
gene	O
,	O
most	O
frequently	O
BRCA1	B-GP
or	O
BRCA2	B-GP
[	O
1	O
].	O

Depending	O
on	O
the	O
type	O
of	O
mutation	O
and	O
the	O
presence	O
of	O
genetic	O
modifiers	O
,	O
this	O
risk	O
can	O
increase	O
to	O
more	O
than	O
80	O
%	O
[	O
2	O
,	O
3	O
].	O

Mammary	O
gland	O
architecture	O
is	O
dynamic	O
and	O
changes	O
during	O
puberty	O
,	O
pregnancy	O
,	O
lactation	O
and	O
involution	O
post	O
partum	O
and	O
post	O
menopause	O
[	O
4	O
,	O
5	O
].	O

At	O
puberty	O
,	O
the	O
mouse	B-OG
mammary	O
ductal	O
system	O
starts	O
growing	O
from	O
the	O
nipple	O
to	O
fill	O
up	O
the	O
mammary	O
fat	O
pad	O
at	O
the	O
age	O
of	O
3	O
-	O
12	O
weeks	O
.	O

The	O
epithelial	O
lining	O
consists	O
of	O
luminal	O
cells	O
that	O
produce	O
milk	O
,	O
and	O
myoepithelial	O
cells	O
that	O
are	O
responsible	O
for	O
contraction	O
during	O
lactation	O
[	O
4	O
].	O

Different	O
theories	O
regarding	O
the	O
mammary	O
stem	O
cell	O
exist	O
.	O

One	O
model	O
proposes	O
the	O
existence	O
of	O
basal	O
stem	O
cells	O
with	O
the	O
property	O
of	O
generating	O
both	O
luminal	O
and	O
basal	O
/	O
myoepithelial	O
lineages	O
[	O
6	O
,	O
7	O
].	O

Another	O
hypothesis	O
is	O
that	O
luminal	O
and	O
basal	O
/	O
myoepithelial	O
are	O
generated	O
by	O
a	O
committed	O
lineage	O
-	O
restricted	O
progenitor	O
cell	O
[	O
8	O
].	O

Although	O
controversy	O
still	O
surrounds	O
the	O
field	O
,	O
current	O
evidence	O
points	O
to	O
a	O
scenario	O
whereby	O
a	O
luminal	O
progenitor	O
may	O
be	O
at	O
the	O
origin	O
of	O
basal	O
-	O
like	O
BRCA	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
[	O
9	O
,	O
10	O
].	O

Standard	O
treatment	O
of	O
BRCA1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
does	O
not	O
differ	O
from	O
other	O
types	O
of	O
breast	B-DS
cancer	I-DS
,	O
although	O
targeted	O
approaches	O
are	O
emerging	O
.	O

However	O
,	O
because	O
BRCA	B-GP
-	O
deficient	O
cells	O
are	O
unable	O
to	O
correct	O
stalled	O
DNA	O
replication	O
forks	O
via	O
homologous	O
repair	O
,	O
these	O
cells	O
are	O
sensitive	O
to	O
platinum	O
-	O
based	O
chemotherapeutics	O
that	O
arrest	O
replication	O
[	O
11	O
-	O
15	O
].	O

Accordingly	O
,	O
BRCA	B-GP
-	O
deficient	O
cells	O
are	O
more	O
sensitive	O
to	O
poly	B-GP
(	I-GP
ADP	I-GP
)-	I-GP
ribose	I-GP
polymerase	I-GP
1	I-GP
(	O
PARP1	B-GP
)	O
inhibition	O
,	O
which	O
is	O
involved	O
in	O
base	O
excision	O
repair	O
[	O
16	O
].	O

Clinical	O
trials	O
have	O
already	O
tested	O
the	O
efficacy	O
of	O
pharmacological	O
inhibition	O
of	O
PARP	B-GP
with	O
overall	O
promising	O
results	O
[	O
17	O
-	O
24	O
].	O

The	O
only	O
effective	O
preventive	O
options	O
for	O
BRCA	B-GP
mutation	O
carriers	O
are	O
currently	O
bilateral	O
prophylactic	O
mastectomy	O
(	O
PM	O
)	O
and	O
prophylactic	O
bilateral	O
salpingo	O
-	O
oophorectomy	O
(	O
PBSO	O
).	O

PM	O
yields	O
a	O
risk	O
reducing	O
effect	O
of	O
more	O
than	O
90	O
-	O
100	O
%	O
in	O
healthy	O
BRCA1	B-GP
and	O
BRCA2	B-GP
mutation	O
carriers	O
[	O
25	O
-	O
27	O
]	O
and	O
PBSO	O
decreases	O
breast	B-DS
cancer	I-DS
risk	O
in	O
BRCA	B-GP
mutation	O
carriers	O
without	O
prior	O
breast	B-DS
cancer	I-DS
approximately	O
by	O
50	O
%	O
[	O
26	O
,	O
28	O
,	O
29	O
].	O

An	O
alternative	O
and	O
less	O
invasive	O
preventive	O
strategy	O
option	O
is	O
the	O
use	O
of	O
hormonal	O
therapy	O
as	O
chemo	O
prevention	O
.	O

Inhibition	O
of	O
estrogen	B-GP
receptor	I-GP
function	O
decreases	O
breast	B-DS
cancer	I-DS
risk	O
in	O
healthy	O
BRCA2	B-GP
mutation	O
carriers	O
,	O
but	O
not	O
in	O
BRCA1	B-GP
mutation	O
carriers	O
[	O
30	O
].	O

Alternatively	O
,	O
cancer	B-DS
-	O
related	O
mortality	O
in	O
BRCA	B-GP
mutation	O
carriers	O
may	O
be	O
managed	O
through	O
intensive	O
surveillance	O
using	O
mammography	O
and	O
MRI	O
,	O
or	O
biomarkers	O
in	O
nipple	O
fluid	O
like	O
methylation	O
[	O
31	O
].	O

Efficiency	O
of	O
this	O
approach	O
however	O
is	O
limited	O
because	O
of	O
high	O
breast	O
tissue	O
density	O
in	O
young	O
women	O
and	O
the	O
aggressive	O
,	O
fast	O
developing	O
nature	O
of	O
BRCA	B-GP
-	O
associated	O
breast	B-DS
tumors	I-DS
.	O

Annual	O
MRI	O
detects	O
the	O
majority	O
of	O
breast	B-DS
cancers	I-DS
at	O
an	O
early	O
and	O
favorable	O
stage	O
[	O
32	O
,	O
33	O
],	O
but	O
a	O
drawback	O
of	O
MRI	O
is	O
the	O
higher	O
rate	O
of	O
false	O
-	O
positive	O
results	O
leading	O
to	O
biopsies	O
of	O
non	O
-	O
diseased	O
tissue	O
and	O
distress	O
[	O
34	O
-	O
37	O
].	O

An	O
alternative	O
and	O
attractive	O
way	O
to	O
prevent	O
breast	B-DS
cancer	I-DS
development	O
in	O
BRCA	B-GP
mutation	O
carriers	O
may	O
be	O
the	O
local	O
administration	O
of	O
ablative	O
agents	O
to	O
the	O
mammary	O
ductal	O
system	O
via	O
the	O
nipple	O
.	O

Preclinical	O
studies	O
in	O
which	O
chemotherapeutics	O
were	O
used	O
intraductally	O
(	O
ID	O
),	O
such	O
as	O
pegylated	O
liposomal	O
doxorubicin	O
(	O
PLD	O
),	O
5	O
-	O
fluorouracil	O
,	O
carboplatin	O
,	O
methotrexate	O
,	O
and	O
paclitaxel	O
,	O
show	O
promising	O
results	O
[	O
38	O
-	O
40	O
].	O

ID	O
chemotherapy	O
was	O
also	O
explored	O
in	O
phase	O
I	O
trials	O
in	O
women	O
with	O
ductal	B-DS
carcinoma	I-DS
in	I-DS
situ	I-DS
(	O
DCIS	B-DS
)	O
and	O
invasive	B-DS
breast	I-DS
cancer	I-DS
prior	O
to	O
mastectomy	O
,	O
where	O
ID	O
administration	O
of	O
PLD	O
and	O
cisplatin	O
was	O
well	O
tolerated	O
with	O
mild	O
adverse	O
events	O
.	O

Moreover	O
,	O
pathological	O
changes	O
could	O
be	O
found	O
in	O
the	O
treated	O
ducts	O
[	O
40	O
-	O
42	O
].	O

Here	O
,	O
we	O
explored	O
the	O
efficacy	O
and	O
safety	O
of	O
ID	O
cisplatin	O
treatment	O
as	O
an	O
alternative	O
prophylactic	O
therapy	O
in	O
the	O
prevention	O
of	O
BRCA1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
formation	O
,	O
in	O
combination	O
with	O
PARP	B-GP
-	O
inhibition	O
.	O

RESULTS	O

Intraductal	O
cisplatin	O
reduces	O
repopulating	O
capacity	O
of	O
the	O
mammary	O
gland	O

To	O
test	O
the	O
effect	O
of	O
ID	O
administered	O
platinum	O
on	O
ductal	O
outgrowth	O
,	O
we	O
injected	O
post	O
-	O
breeder	O
wild	O
type	O
mice	B-OG
(	O
ranging	O
in	O
age	O
between	O
12	O
-	O
30	O
weeks	O
;	O
primiparous	O
;	O
average	O
litter	O
size	O
of	O
7	O
;	O
mean	O
time	O
post	O
weaning	O
of	O
42	O
days	O
)	O
twice	O
with	O
ID	O
cisplatin	O
in	O
gland	O
number	O
3	O
,	O
4	O
,	O
and	O
5	O
on	O
the	O
right	O
side	O
and	O
with	O
control	O
on	O
the	O
left	O
side	O
with	O
a	O
4	O
-	O
week	O
interval	O
(	O
Figure	O
1A	O
).	O

One	O
week	O
after	O
the	O
second	O
treatment	O
,	O
we	O
isolated	O
mouse	B-OG
mammary	O
epithelial	O
cells	O
(	O
MMECs	O
)	O
from	O
the	O
3rd	O
and	O
4th	O
mammary	O
glands	O
that	O
were	O
injected	O
into	O
the	O
cleared	O
mammary	O
fat	O
pad	O
of	O
3	O
-	O
week	O
old	O
syngeneic	O
recipient	O
mice	B-OG
.	O

ID	O
cisplatin	O
significantly	O
lowered	O
outgrowth	O
after	O
transplantation	O
compared	O
to	O
control	O
injection	O
(	O
p	O
=	O
0	O
.	O
010	O
;	O
Figure	O
1B	O
;	O
1C	O
).	O

Whole	O
mount	O
analysis	O
showed	O
ductal	O
outgrowth	O
in	O
17	O
of	O
18	O
(	O
94	O
.	O
4	O
%)	O
transplantations	O
of	O
the	O
control	O
-	O
treated	O
mammary	O
glands	O
and	O
in	O
11	O
of	O
19	O
transplantations	O
in	O
the	O
cisplatin	O
-	O
treated	O
glands	O
(	O
57	O
.	O
9	O
%),	O
of	O
which	O
2	O
showed	O
only	O
rudimentary	O
duct	O
formation	O
.	O

ID	O
cisplatin	O
treatment	O
reduces	O
epithelial	O
viability	O
and	O
leads	O
to	O
an	O
inhibition	O
of	O
mammary	O
gland	O
repopulation	O

A	O
.	O
Experimental	O
set	O
-	O
up	O
.	O

Post	O
-	O
breeder	O
mice	B-OG
were	O
subjected	O
to	O
2	O
ID	O
cisplatin	O
treatments	O
with	O
a	O
4	O
-	O
week	O
interval	O
in	O
the	O
right	O
-	O
sided	O
glands	O
number	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

The	O
contralateral	O
corresponding	O
mammary	O
glands	O
served	O
as	O
control	O
.	O

Next	O
,	O
MMECs	O
were	O
harvested	O
and	O
transplanted	O
into	O
syngeneic	O
mice	B-OG
(	O
upper	O
part	O
)	O
or	O
analyzed	O
by	O
FACS	O
(	O
lower	O
part	O
).	O
B	O
.	O
and	O
C	O
.	O
Cisplatin	O
inhibits	O
the	O
mammary	O
repopulating	O
capacity	O
.	O

Depicted	O
are	O
representative	O
samples	O
of	O
whole	O
mount	O
analyses	O
,	O
showing	O
complete	O
outgrowth	O
after	O
control	O
treatment	O
(	O
B	O
;	O
left	O
),	O
rudimentary	O
outgrowth	O
(	O
B	O
;	O
middle	O
),	O
or	O
no	O
outgrowth	O
(	O
B	O
;	O
right	O
)	O
after	O
ID	O
cisplatin	O
treatment	O
.	O

Quantifications	O
of	O
the	O
control	O
(	O
left	O
pie	O
chart	O
)	O
and	O
ID	O
cisplatin	O
treated	O
glands	O
(	O
right	O
pie	O
chart	O
)	O
are	O
shown	O
in	O
(	O
C	O
).	O
D	O
.	O
and	O
E	O
.	O
ID	O
cisplatin	O
treatment	O
leads	O
to	O
an	O
overall	O
reduction	O
of	O
MMECs	O
.	O

Representative	O
plots	O
of	O
the	O
basal	O
and	O
luminal	O
cell	O
populations	O
using	O
FACS	O
analysis	O
after	O
control	O
(	O
D	O
;	O
left	O
dot	O
plot	O
),	O
or	O
ID	O
cisplatin	O
treatment	O
(	O
D	O
;	O
right	O
dot	O
plot	O
).	O

Quantifications	O
of	O
basal	O
and	O
luminal	O
MMECs	O
are	O
shown	O
in	O
(	O
E	O
).	O

Basal	O
MMECs	O
were	O
defined	O
as	O
DAPI	O
-;	O
CD45	B-GP
-;	O
Sca	B-GP
-;	O
CD24	B-GP
+/	O
low	O
and	O
luminal	O
MMECs	O
as	O
DAPI	O
-;	O
CD45	B-GP
-;	O
Sca	B-GP
-	O
or	O
+;	O
CD24	B-GP
+/	O
hi	O
.	O

Shown	O
is	O
an	O
average	O
of	O
9	O
mice	B-OG
per	O
condition	O
.	O

Error	O
bars	O
represent	O
SEM	O
;	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
.	O
F	O
.	O
Cisplatin	O
-	O
treated	O
glands	O
showed	O
morphological	O
changes	O
matching	O
apoptosis	O
and	O
an	O
induction	O
of	O
cleaved	O
caspase	B-GP
3	I-GP
expression	O
in	O
the	O
epithelial	O
lining	O
of	O
the	O
mammary	O
duct	O
.	O

Representative	O
pictures	O
of	O
H	O
&	O
E	O
and	O
cleaved	O
caspase	B-GP
3	I-GP
stainings	O
of	O
mammary	O
gland	O
tissue	O
slides	O
after	O
ID	O
cisplatin	O
treatment	O
are	O
shown	O
.	O

Scale	O
bar	O
is	O
100	O
μm	O
,	O
upper	O
right	O
pictures	O
are	O
blow	O
-	O
ups	O
of	O
caspase	B-GP
3	I-GP
positive	O
cells	O
.	O

Next	O
,	O
we	O
performed	O
FACS	O
analysis	O
,	O
which	O
indicated	O
that	O
ID	O
administered	O
cisplatin	O
induced	O
a	O
significant	O
and	O
uniform	O
reduction	O
in	O
the	O
basal	O
and	O
luminal	O
populations	O
(	O
p	O
=	O
0	O
.	O
008	O
compared	O
to	O
control	O
for	O
luminal	O
,	O
and	O
p	O
<	O
0	O
.	O
001	O
for	O
basal	O
population	O
in	O
n	O
=	O
9	O
analyzed	O
glands	O
;	O
Figure	O
1D	O
;	O
1E	O
).	O

The	O
effect	O
of	O
cisplatin	O
appeared	O
to	O
specifically	O
reduce	O
the	O
epithelial	O
mammary	O
cells	O
,	O
since	O
the	O
number	O
of	O
non	O
-	O
epithelial	O
cells	O
was	O
not	O
decreased	O
proportionally	O
after	O
ID	O
treatment	O
(	O
Figure	O
1D	O
;	O
upper	O
left	O
quadrant	O
).	O

Further	O
,	O
we	O
observed	O
that	O
cisplatin	O
-	O
treated	O
glands	O
showed	O
an	O
induction	O
of	O
cleaved	O
caspase	B-GP
3	I-GP
expression	O
in	O
the	O
epithelial	O
lining	O
of	O
the	O
mammary	O
duct	O
(	O
Figure	O
1F	O
).	O

We	O
therefore	O
conclude	O
that	O
ID	O
cisplatin	O
treatment	O
reduces	O
the	O
repopulating	O
capacity	O
of	O
the	O
wild	O
type	O
mammary	O
gland	O
.	O

Intraductal	O
cisplatin	O
impairs	O
lobulo	O
-	O
alveolar	O
development	O

To	O
assess	O
the	O
effect	O
of	O
treatment	O
on	O
pregnancy	O
-	O
associated	O
lobulo	O
-	O
alveolar	O
development	O
,	O
we	O
analyzed	O
mammary	O
gland	O
whole	O
mounts	O
after	O
ID	O
treatment	O
of	O
both	O
non	O
-	O
pregnant	O
and	O
pregnant	O
mice	B-OG
(	O
Figure	O
2A	O
).	O

ID	O
cisplatin	O
reduced	O
ductulo	O
-	O
lobular	O
outgrowth	O
in	O
both	O
non	O
-	O
pregnant	O
and	O
pregnant	O
mice	B-OG
.	O

Representative	O
whole	O
mounts	O
and	O
corresponding	O
H	O
&	O
E	O
and	O
β	B-GP
-	I-GP
casein	I-GP
stainings	O
are	O
shown	O
in	O
Figure	O
2B	O
.	O

In	O
all	O
control	O
mammary	O
glands	O
from	O
both	O
non	O
-	O
pregnant	O
and	O
pregnant	O
mice	B-OG
,	O
ductal	O
outgrowth	O
and	O
alveolar	O
differentiation	O
was	O
uniform	O
and	O
complete	O
.	O

ID	O
cisplatin	O
showed	O
no	O
effect	O
in	O
13	O
glands	O
of	O
23	O
non	O
-	O
pregnant	O
mice	B-OG
(	O
56	O
.	O
6	O
%),	O
partial	O
effect	O
in	O
5	O
(	O
21	O
.	O
7	O
%),	O
subtotal	O
in	O
4	O
(	O
17	O
.	O
4	O
%),	O
and	O
total	O
effect	O
in	O
1	O
(	O
4	O
.	O
3	O
%)	O
(	O
Figure	O
2C	O
).	O

In	O
pregnant	O
mice	B-OG
ID	O
cisplatin	O
did	O
not	O
lead	O
to	O
an	O
inhibition	O
of	O
alveolar	O
development	O
in	O
12	O
of	O
21	O
mice	B-OG
(	O
57	O
.	O
1	O
%),	O
while	O
we	O
observed	O
a	O
partial	O
response	O
in	O
2	O
(	O
9	O
.	O
5	O
%),	O
subtotal	O
in	O
4	O
(	O
19	O
.	O
0	O
%),	O
and	O
total	O
response	O
in	O
3	O
(	O
14	O
.	O
3	O
%)	O
glands	O
(	O
Figure	O
2D	O
).	O

In	O
summary	O
,	O
ID	O
cisplatin	O
administration	O
induced	O
a	O
significant	O
reduction	O
in	O
ductal	O
outgrowth	O
(	O
defined	O
as	O
(	O
sub	O
)	O
total	O
effect	O
)	O
in	O
both	O
non	O
-	O
pregnant	O
and	O
pregnant	O
mice	B-OG
(	O
p	O
=	O
0	O
.	O
018	O
and	O
0	O
.	O
004	O
,	O
respectively	O
).	O

Functional	O
effect	O
of	O
ID	O
cisplatin	O
on	O
the	O
mammary	O
gland	O
and	O
pregnancy	O
-	O
induced	O
lobulo	O
-	O
alveolar	O
development	O

A	O
.	O
Experimental	O
set	O
-	O
up	O
.	O

Post	O
-	O
breeder	O
mice	B-OG
were	O
subjected	O
to	O
two	O
ID	O
cisplatin	O
treatments	O
with	O
a	O
4	O
-	O
week	O
interval	O
in	O
the	O
right	O
-	O
sided	O
glands	O
number	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

The	O
contralateral	O
corresponding	O
mammary	O
glands	O
served	O
as	O
control	O
.	O

Next	O
,	O
whole	O
mounts	O
were	O
analyzed	O
at	O
day	O
17	O
.	O
5	O
of	O
pregnancy	O
or	O
at	O
a	O
similar	O
time	O
point	O
in	O
non	O
-	O
pregnant	O
mice	B-OG
.	O
B	O
.	O
Representative	O
pictures	O
showing	O
no	O
effect	O
in	O
control	O
(	O
first	O
column	O
)	O
or	O
partial	O
(	O
second	O
column	O
),	O
subtotal	O
(	O
third	O
column	O
),	O
or	O
total	O
effect	O
(	O
fourth	O
column	O
)	O
after	O
ID	O
cisplatin	O
treatment	O
.	O

The	O
top	O
two	O
rows	O
show	O
whole	O
mount	O
analyses	O
,	O
followed	O
by	O
H	O
&	O
E	O
stainings	O
,	O
and	O
β	B-GP
-	I-GP
casein	I-GP
IHC	O
.	O

Scale	O
bar	O
is	O
100	O
μm	O
in	O
lower	O
magnifications	O
and	O
50	O
μm	O
in	O
higher	O
magnifications	O
.	O
C	O
.	O
ID	O
cisplatin	O
reduces	O
ductal	O
outgrowth	O
in	O
non	O
-	O
pregnant	O
mice	B-OG
(	O
n	O
=	O
23	O
).	O

Quantifications	O
of	O
mammary	O
ductal	O
outgrowth	O
after	O
control	O
(	O
left	O
chart	O
)	O
or	O
ID	O
cisplatin	O
treatment	O
(	O
right	O
chart	O
).	O
D	O
.	O
ID	O
cisplatin	O
reduces	O
lobulo	O
-	O
alveolar	O
development	O
in	O
pregnant	O
mice	B-OG
(	O
n	O
=	O
21	O
).	O

Quantifications	O
of	O
mammary	O
ductal	O
outgrowth	O
after	O
control	O
(	O
left	O
chart	O
)	O
or	O
ID	O
cisplatin	O
treatment	O
(	O
right	O
chart	O
).	O

Intraductal	O
cisplatin	O
and	O
olaparib	O
increase	O
tumor	B-DS
-	O
free	O
latency	O
in	O
a	O
mouse	B-OG
model	O
of	O
BRCA1	B-GP
-	O
associated	O
human	B-OG
breast	B-DS
cancer	I-DS

We	O
next	O
investigated	O
the	O
preventive	O
effect	O
of	O
ID	O
cisplatin	O
in	O
a	O
mouse	B-OG
model	O
for	O
BRCA1	B-GP
-	O
associated	O
human	B-OG
breast	B-DS
cancer	I-DS
.	O

Since	O
tumors	B-DS
in	O
a	O
K14cre	O
-	O
driven	O
variant	O
of	O
this	O
model	O
were	O
highly	O
sensitive	O
to	O
a	O
combination	O
of	O
cisplatin	O
and	O
the	O
PARP	B-GP
-	O
inhibitor	O
olaparib	O
[	O
14	O
],	O
we	O
tested	O
both	O
prophylactic	O
monotherapies	O
and	O
the	O
combination	O
of	O
ID	O
cisplatin	O
and	O
olaparib	O
in	O
the	O
whey	B-GP
acidic	I-GP
protein	I-GP
(	O
WAP	B-GP
)	O
cre	B-GP
-	O
driven	O
tumor	B-DS
model	O
.	O

We	O
chose	O
the	O
WAPcre	O
model	O
for	O
our	O
studies	O
because	O
the	O
overt	O
induction	O
of	O
skin	B-DS
tumors	I-DS
in	O
the	O
K14cre	O
models	O
interferes	O
with	O
the	O
analysis	O
of	O
mammary	B-DS
tumor	I-DS
formation	O
[	O
43	O
].	O

Tumor	B-DS
latency	O
and	O
incidence	O
in	O
the	O
WAPCre	O
;	O
Brca1F	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
model	O
are	O
shown	O
in	O
Supplementary	O
Figure	O
S1	O
and	O
PCR	O
results	O
of	O
tumors	B-DS
in	O
Supplemental	O
Figure	O
2	O
.	O

Female	O
virgin	O
WAPcre	O
;	O
Brca1F	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
mice	B-OG
were	O
injected	O
twice	O
in	O
glands	O
3	O
and	O
4	O
.	O

Either	O
all	O
third	O
and	O
fourth	O
glands	O
were	O
treated	O
with	O
control	O
or	O
all	O
4	O
treated	O
glands	O
were	O
injected	O
with	O
cisplatin	O
at	O
the	O
age	O
of	O
12	O
and	O
16	O
weeks	O
.	O

Prior	O
,	O
during	O
and	O
post	O
ID	O
cisplatin	O
treatment	O
,	O
mice	B-OG
were	O
daily	O
injected	O
intraperitoneally	O
(	O
IP	O
)	O
with	O
control	O
or	O
olaparib	O
and	O
followed	O
for	O
tumor	B-DS
formation	O
(	O
Figure	O
3A	O
).	O

ID	O
cisplatin	O
monotherapy	O
significantly	O
increased	O
the	O
median	O
tumor	B-DS
-	O
free	O
latency	O
(	O
T50	O
)	O
in	O
ID	O
injected	O
glands	O
from	O
153	O
days	O
in	O
control	O
to	O
210	O
days	O
in	O
cisplatin	O
treated	O
mice	B-OG
(	O
p	O
<	O
0	O
.	O
0001	O
;	O
Figure	O
3B	O
).	O

IP	O
treatment	O
using	O
olaparib	O
monotherapy	O
also	O
led	O
to	O
an	O
increase	O
in	O
tumor	B-DS
-	O
free	O
latency	O
(	O
T50	O
=	O
203	O
versus	O
153	O
days	O
;	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
3B	O
).	O

Moreover	O
,	O
using	O
a	O
combination	O
therapy	O
of	O
ID	O
cisplatin	O
and	O
IP	O
olaparib	O
,	O
we	O
observed	O
an	O
increase	O
in	O
T50	O
from	O
153	O
to	O
239	O
days	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
3B	O
).	O

Dual	O
therapy	O
using	O
ID	O
cisplatin	O
and	O
olaparib	O
led	O
to	O
a	O
longer	O
tumor	B-DS
-	O
free	O
latency	O
compared	O
to	O
olaparib	O
monotherapy	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
but	O
not	O
compared	O
to	O
cisplatin	O
monotherapy	O
(	O
p	O
=	O
0	O
.	O
506	O
).	O

Combined	O
prophylactic	O
cisplatin	O
and	O
olaparib	O
treatment	O
in	O
a	O
WAPCre	O
;	O
Brca1F	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
sporadic	O
mouse	B-OG
model	O
leads	O
to	O
a	O
later	O
onset	O
of	O
breast	B-DS
tumor	I-DS
formation	O

A	O
.	O
Experimental	O
set	O
-	O
up	O
.	O

Virgin	O
WAPCre	O
;	O
Brca1F	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
were	O
treated	O
twice	O
in	O
glands	O
number	O
3	O
and	O
4	O
with	O
either	O
control	O
or	O
cisplatin	O
at	O
the	O
age	O
of	O
12	O
and	O
16	O
weeks	O
.	O

During	O
the	O
ID	O
treatments	O
,	O
mice	B-OG
were	O
IP	O
injected	O
with	O
control	O
or	O
olaparib	O
on	O
a	O
daily	O
basis	O
from	O
the	O
age	O
of	O
10	O
to	O
18	O
weeks	O
.	O

In	O
total	O
4	O
treatment	O
groups	O
were	O
analyzed	O
,	O
i	O
.	O
e	O
.	O
control	O
(	O
n	O
=	O
24	O
),	O
ID	O
cisplatin	O
monotherapy	O
(	O
n	O
=	O
20	O
),	O
IP	O
olaparib	O
monotherapy	O
(	O
n	O
=	O
29	O
)	O
and	O
ID	O
cisplatin	O
combined	O
with	O
IP	O
olaparib	O
combination	O
therapy	O
(	O
n	O
=	O
27	O
).	O
B	O
.	O
Kaplan	O
-	O
Meier	O
curves	O
showing	O
the	O
tumor	B-DS
-	O
free	O
latency	O
post	O
treatment	O
of	O
mammary	O
glands	O
tumor	B-DS
in	O
the	O
treated	O
(	O
glands	O
number	O
3	O
and	O
4	O
;	O
left	O
graph	O
)	O
and	O
untreated	O
mammary	O
glands	O
(	O
glands	O
number	O
1	O
,	O
2	O
,	O
and	O
5	O
;	O
right	O
graph	O
).	O

Strikingly	O
,	O
similar	O
effects	O
were	O
obtained	O
when	O
analyzing	O
untreated	O
mammary	O
glands	O
,	O
i	O
.	O
e	O
.	O
glands	O
number	O
1	O
,	O
2	O
and	O
5	O
.	O

Here	O
,	O
the	O
T50	O
increased	O
significantly	O
from	O
157	O
days	O
in	O
control	O
to	O
225	O
days	O
in	O
cisplatin	O
treated	O
animals	B-OG
(	O
p	O
<	O
0	O
.	O
0001	O
;	O
Figure	O
3B	O
).	O

Olaparib	O
induced	O
an	O
increase	O
in	O
T50	O
to	O
219	O
days	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
and	O
combination	O
treatment	O
led	O
to	O
T50	O
of	O
241	O
days	O
(	O
p	O
<	O
0	O
.	O
0001	O
;	O
Figure	O
3B	O
),	O
suggesting	O
that	O
local	O
ID	O
treatment	O
results	O
in	O
systemic	O
exposure	O
and	O
subsequent	O
inhibition	O
of	O
tumor	B-DS
development	O
.	O

ID	O
cisplatin	O
reduced	O
tumor	B-DS
incidence	O
in	O
the	O
locally	O
treated	O
gland	O
to	O
85	O
.	O
0	O
%	O
(	O
p	O
=	O
0	O
.	O
086	O
compared	O
to	O
control	O
).	O

For	O
olaparib	O
this	O
was	O
89	O
.	O
7	O
%	O
(	O
p	O
=	O
0	O
.	O
242	O
),	O
and	O
in	O
the	O
combination	O
group	O
tumor	B-DS
incidence	O
was	O
81	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
052	O
).	O

Monotherapy	O
with	O
cisplatin	O
ID	O
did	O
not	O
significantly	O
differ	O
from	O
olaparib	O
monotherapy	O
regarding	O
tumor	B-DS
incidence	O
(	O
p	O
=	O
0	O
.	O
677	O
).	O

Also	O
,	O
a	O
dual	O
ID	O
cisplatin	O
and	O
olaparib	O
treatment	O
was	O
not	O
significantly	O
better	O
than	O
either	O
monotherapies	O
.	O

Tumor	B-DS
incidence	O
of	O
the	O
untreated	O
glands	O
decreased	O
to	O
85	O
.	O
0	O
%	O
in	O
cisplatin	O
(	O
p	O
=	O
0	O
.	O
086	O
),	O
75	O
.	O
9	O
%	O
in	O
olaparib	O
(	O
p	O
=	O
0	O
.	O
012	O
),	O
and	O
66	O
.	O
7	O
%	O
in	O
the	O
combination	O
treatment	O
group	O
(	O
p	O
=	O
0	O
.	O
002	O
).	O

Metastases	O
formation	O
did	O
not	O
significantly	O
change	O
between	O
different	O
treatment	O
groups	O
(	O
Supplementary	O
Table	O
S1	O
).	O

In	O
short	O
,	O
a	O
combination	O
of	O
ID	O
cisplatin	O
with	O
systemic	O
olaparib	O
increases	O
tumor	B-DS
-	O
free	O
latency	O
in	O
a	O
mouse	B-OG
model	O
of	O
Brca1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
.	O

However	O
,	O
ID	O
injection	O
leads	O
to	O
systemic	O
exposure	O
of	O
cisplatin	O
.	O

Pharmacokinetics	O
of	O
intraductal	O
cisplatin	O

To	O
determine	O
the	O
extent	O
of	O
systemic	O
exposure	O
to	O
platinum	O
after	O
ID	O
injection	O
,	O
we	O
harvested	O
plasma	O
samples	O
after	O
ID	O
treatment	O
with	O
cisplatin	O
injection	O
of	O
the	O
3rd	O
and	O
4th	O
mammary	O
glands	O
of	O
12	O
week	O
old	O
wild	O
type	O
mice	B-OG
(	O
Figure	O
4A	O
).	O

Highest	O
plasma	O
concentrations	O
were	O
measured	O
15	O
minutes	O
after	O
treatment	O
with	O
an	O
average	O
of	O
4	O
.	O
6	O
μg	O
/	O
ml	O
(	O
Figure	O
4B	O
).	O

After	O
5	O
minutes	O
,	O
platinum	O
was	O
detected	O
in	O
plasma	O
with	O
a	O
mean	O
concentration	O
of	O
1	O
.	O
0	O
μg	O
/	O
ml	O
when	O
injecting	O
one	O
mammary	O
gland	O
.	O

After	O
96	O
hours	O
the	O
AUC	O
value	O
was	O
45	O
.	O
6	O
μg	O
•	O
ml	O
/	O
h	O
,	O
comparable	O
to	O
a	O
reported	O
AUC	O
of	O
47	O
.	O
9	O
μg	O
•	O
ml	O
/	O
h	O
after	O
intra	O
-	O
tumoral	O
(	O
IT	O
)	O
injection	O
of	O
a	O
similar	O
dose	O
of	O
cisplatin	O
[	O
44	O
].	O

Pharmacokinetics	O
of	O
the	O
ID	O
cisplatin	O
treatment	O

A	O
.	O
Experimental	O
set	O
-	O
up	O
.	O

Virgin	O
wild	O
type	O
mice	B-OG
were	O
treated	O
with	O
ID	O
cisplatin	O
in	O
glands	O
number	O
3	O
and	O
4	O
at	O
the	O
age	O
of	O
12	O
weeks	O
.	O

Mice	B-OG
were	O
sacrificed	O
at	O
different	O
time	O
points	O
after	O
ID	O
injections	O
(	O
see	O
text	O
for	O
details	O
,	O
n	O
=	O
3	O
mice	B-OG
per	O
time	O
point	O
)	O
and	O
plasma	O
and	O
mammary	O
gland	O
tissue	O
samples	O
were	O
harvested	O
.	O
B	O
.	O
Plasma	O
platinum	O
concentrations	O
after	O
ID	O
treatment	O
.	O

Shown	O
are	O
the	O
average	O
concentrations	O
per	O
time	O
point	O
with	O
SEM	O
.	O
C	O
.	O
Mammary	O
gland	O
platinum	O
concentrations	O
after	O
ID	O
cisplatin	O
treatment	O
.	O

The	O
black	O
line	O
shows	O
the	O
concentrations	O
in	O
untreated	O
glands	O
(	O
gland	O
number	O
2	O
).	O

The	O
pink	O
line	O
depicts	O
the	O
concentrations	O
in	O
the	O
treated	O
mammary	O
glands	O
(	O
gland	O
number	O
4	O
).	O

Shown	O
are	O
the	O
average	O
concentrations	O
per	O
time	O
point	O
with	O
SEM	O
;	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
.	O

We	O
also	O
determined	O
platinum	O
tissue	O
concentrations	O
in	O
locally	O
treated	O
and	O
distant	O
untreated	O
mammary	O
glands	O
(	O
4th	O
and	O
2nd	O
mammary	O
glands	O
,	O
respectively	O
,	O
see	O
Figure	O
4C	O
).	O

Concentrations	O
peaked	O
at	O
15	O
minutes	O
with	O
a	O
mean	O
platinum	O
concentration	O
of	O
3	O
.	O
32	O
μg	O
/	O
ml	O
in	O
locally	O
treated	O
versus	O
0	O
.	O
99	O
μg	O
/	O
ml	O
in	O
the	O
untreated	O
glands	O
.	O

Platinum	O
concentrations	O
in	O
the	O
untreated	O
glands	O
were	O
significantly	O
lower	O
than	O
in	O
locally	O
treated	O
glands	O
(	O
p	O
=	O
0	O
.	O
015	O
).	O

After	O
96	O
hours	O
the	O
AUC	O
value	O
of	O
locally	O
treated	O
glands	O
was	O
18	O
.	O
75	O
μg	O
•	O
ml	O
/	O
h	O
compared	O
to	O
4	O
.	O
73	O
μg	O
•	O
ml	O
/	O
h	O
in	O
systemically	O
treated	O
glands	O
,	O
which	O
is	O
25	O
.	O
2	O
%	O
of	O
the	O
locally	O
exposed	O
glands	O
.	O

Long	O
-	O
term	O
local	O
and	O
systemic	O
effects	O
of	O
intraductal	O
cisplatin	O

To	O
serve	O
as	O
an	O
alternative	O
prophylaxis	O
in	O
young	O
BRCA	B-GP
-	O
mutation	O
carriers	O
,	O
long	O
-	O
term	O
carcinogenicity	O
of	O
ID	O
cisplatin	O
must	O
be	O
minimal	O
.	O

To	O
test	O
this	O
,	O
we	O
ID	O
injected	O
the	O
3rd	O
and	O
4th	O
mammary	O
glands	O
of	O
post	O
-	O
pubertal	O
wild	O
type	O
mice	B-OG
at	O
the	O
age	O
of	O
12	O
and	O
16	O
weeks	O
with	O
either	O
control	O
(	O
n	O
=	O
67	O
)	O
or	O
cisplatin	O
(	O
n	O
=	O
86	O
),	O
which	O
were	O
followed	O
longitudinally	O
until	O
death	O
or	O
disease	O
(	O
Figure	O
5A	O
).	O

Due	O
to	O
early	O
death	O
caused	O
by	O
mammary	B-DS
tumor	I-DS
formation	O
in	O
the	O
mouse	B-OG
model	O
carrying	O
conditional	O
homozygous	O
Trp53	B-GP
alleles	O
we	O
,	O
used	O
allogeneic	O
wild	O
-	O
type	O
mice	B-OG
for	O
long	O
-	O
term	O
carcinogenicity	O
studies	O
.	O

Although	O
ID	O
treatment	O
of	O
cisplatin	O
induced	O
a	O
shorter	O
tumor	B-DS
-	O
free	O
latency	O
based	O
on	O
histopathology	O
data	O
,	O
the	O
reduction	O
in	O
latency	O
was	O
only	O
observed	O
in	O
aged	O
(>	O
560	O
days	O
)	O
mice	B-OG
(	O
Figure	O
5B	O
).	O

Also	O
,	O
we	O
observed	O
an	O
effect	O
on	O
overall	O
survival	O
when	O
comparing	O
treated	O
versus	O
control	O
female	O
mice	B-OG
(	O
p	O
=	O
0	O
.	O
019	O
;	O
Figure	O
5B	O
).	O

Mammary	B-DS
tumors	I-DS
developed	O
more	O
often	O
in	O
the	O
ID	O
cisplatin	O
treated	O
mammary	O
glands	O
(	O
21	O
of	O
336	O
locally	O
treated	O
glands	O
(	O
6	O
.	O
3	O
%))	O
than	O
in	O
control	O
mice	B-OG
(	O
0	O
of	O
252	O
locally	O
treated	O
glands	O
;	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
5C	O
and	O
5D	O
),	O
albeit	O
in	O
aged	O
female	O
mice	B-OG
(	O
679	O
days	O
after	O
the	O
second	O
ID	O
injection	O
),	O
which	O
did	O
not	O
lead	O
to	O
an	O
increase	O
metastatic	O
dissemination	O
.	O

Importantly	O
,	O
tumor	B-DS
incidence	O
in	O
distant	O
untreated	O
glands	O
was	O
increased	O
.	O

Cisplatin	O
treated	O
mice	B-OG
developed	O
breast	B-DS
tumors	I-DS
in	O
untreated	O
glands	O
in	O
3	O
.	O
6	O
%	O
(	O
18	O
of	O
504	O
glands	O
)	O
compared	O
to	O
0	O
.	O
8	O
%	O
in	O
control	O
mice	B-OG
(	O
3	O
of	O
378	O
glands	O
;	O
p	O
=	O
0	O
.	O
007	O
;	O
Figure	O
5C	O
and	O
5D	O
).	O

Finally	O
,	O
primary	O
adenocarcinomas	B-DS
of	I-DS
the	I-DS
lung	I-DS
were	O
found	O
in	O
48	O
.	O
9	O
%	O
in	O
cisplatin	O
versus	O
29	O
.	O
7	O
%	O
in	O
control	O
treated	O
mice	B-OG
(	O
p	O
=	O
0	O
.	O
019	O
;	O
Figure	O
5C	O
).	O

The	O
incidence	O
of	O
gynecological	O
,	O
lymphoproliferative	O
and	O
other	O
tumors	B-DS
did	O
not	O
significantly	O
differ	O
between	O
both	O
treatment	O
groups	O
(	O
p	O
=	O
0	O
.	O
741	O
,	O
0	O
.	O
493	O
and	O
0	O
.	O
692	O
,	O
respectively	O
;	O
Figure	O
5C	O
).	O

Benign	O
pathology	O
of	O
the	O
aged	O
female	O
mice	B-OG
is	O
shown	O
in	O
Supplementary	O
Table	O
S2	O
.	O

Long	O
-	O
term	O
effects	O
of	O
ID	O
cisplatin	O
treatment	O

A	O
.	O
Experimental	O
-	O
set	O
up	O
.	O

Virgin	O
F1	O
(	O
FVB	O
/	O
N	O
;	O
Ola129Hsd	O
)	O
mice	B-OG
were	O
treated	O
twice	O
in	O
glands	O
3	O
and	O
4	O
with	O
either	O
cisplatin	O
or	O
control	O
at	O
the	O
age	O
of	O
12	O
and	O
16	O
weeks	O
.	O

Next	O
,	O
mice	B-OG
were	O
followed	O
in	O
time	O
for	O
tumor	B-DS
development	O
.	O
B	O
.	O
Kaplan	O
-	O
Meier	O
curves	O
showing	O
overall	O
survival	O
of	O
control	O
(	O
black	O
line	O
;	O
n	O
=	O
67	O
)	O
or	O
ID	O
cisplatin	O
(	O
pink	O
line	O
;	O
n	O
=	O
86	O
)	O
treated	O
mice	B-OG
.	O
C	O
.	O
Table	O
showing	O
the	O
incidence	O
of	O
malignancies	O
in	O
control	O
and	O
ID	O
cisplatin	O
treated	O
mice	B-OG
.	O

The	O
category	O
‘	O
other	O
tumors	B-DS
’	O
consisted	O
of	O
sarcoma	B-DS
of	O
unknown	O
origin	O
,	O
hemangiosarcoma	B-DS
of	I-DS
the	I-DS
spleen	I-DS
,	O
carcinoma	B-DS
of	I-DS
the	I-DS
oral	I-DS
cavity	I-DS
,	O
and	O
squamous	B-DS
carcinoma	I-DS
in	O
the	O
anogenital	O
region	O
in	O
control	O
mice	B-OG
.	O

In	O
ID	O
cisplatin	O
treated	O
mice	B-OG
‘	O
other	O
tumors	B-DS
’	O
comprised	O
hepatocellular	B-DS
carcinoma	I-DS
(	O
n	O
=	O
2	O
),	O
carcinoma	B-DS
of	I-DS
the	I-DS
salivary	I-DS
gland	I-DS
,	O
and	O
angiosarcoma	B-DS
in	O
the	O
mammary	O
gland	O
.	O
D	O
.	O
Bar	O
graph	O
showing	O
the	O
breast	B-DS
tumor	I-DS
incidence	O
in	O
control	O
and	O
ID	O
cisplatin	O
treated	O
mice	B-OG
per	O
mammary	O
gland	O
.	O

Given	O
the	O
increase	O
in	O
both	O
local	O
and	O
systemic	O
tumor	B-DS
incidence	O
in	O
mice	B-OG
,	O
we	O
conclude	O
that	O
ID	O
administration	O
of	O
cisplatin	O
under	O
these	O
conditions	O
cannot	O
upfront	O
be	O
regarded	O
as	O
a	O
safe	O
alternative	O
prophylactic	O
therapy	O
to	O
prevent	O
BRCA1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
formation	O
in	O
humans	B-OG
.	O

DISCUSSION	O

ID	O
cisplatin	O
treatment	O
leads	O
to	O
a	O
uniform	O
reduction	O
of	O
the	O
epithelial	O
mammary	O
cells	O
and	O
thereby	O
prolongs	O
breast	B-DS
tumor	I-DS
-	O
free	O
latency	O
in	O
a	O
conditional	O
BRCA1	B-GP
-	O
associated	O
mouse	B-OG
model	O
.	O

However	O
,	O
our	O
results	O
also	O
show	O
that	O
the	O
success	O
rate	O
of	O
ID	O
treatment	O
using	O
cisplatin	O
is	O
variable	O
.	O

Multiple	O
functional	O
assays	O
,	O
including	O
whole	O
mount	O
and	O
transplantation	O
assays	O
,	O
resulted	O
in	O
a	O
successful	O
ablation	O
in	O
approximately	O
half	O
of	O
the	O
recipient	O
mice	B-OG
.	O

This	O
partial	O
effect	O
can	O
be	O
explained	O
by	O
e	O
.	O
g	O
.	O
incomplete	O
injection	O
penetrance	O
,	O
whereby	O
not	O
all	O
ductal	O
branches	O
have	O
been	O
exposed	O
to	O
cisplatin	O
.	O

Moreover	O
,	O
the	O
progenitor	O
cell	O
leading	O
to	O
cancer	B-DS
is	O
presumably	O
a	O
low	O
proliferating	O
cell	O
and	O
as	O
such	O
less	O
susceptible	O
to	O
platinum	O
-	O
based	O
drugs	O
.	O

Another	O
explanation	O
could	O
be	O
the	O
that	O
proliferative	O
differences	O
due	O
to	O
estrus	O
cycling	O
may	O
influence	O
the	O
effectiveness	O
of	O
cisplatin	O
[	O
45	O
,	O
46	O
],	O
which	O
suggests	O
that	O
ID	O
treatment	O
should	O
be	O
tailored	O
to	O
specific	O
estrus	O
stages	O
for	O
successful	O
cisplatin	O
-	O
based	O
prophylaxis	O
.	O

To	O
our	O
surprise	O
,	O
ID	O
cisplatin	O
prolonged	O
tumor	B-DS
-	O
free	O
latency	O
in	O
untreated	O
mammary	O
glands	O
.	O

Since	O
Brca1	B-GP
inactivation	O
and	O
subsequent	O
tumor	B-DS
formation	O
in	O
the	O
WAPcre	O
-	O
driven	O
model	O
occurs	O
during	O
the	O
first	O
estrus	O
cycle	O
(	O
independent	O
of	O
pregnancy	O
-	O
induced	O
WAP	B-GP
activation	O
)	O
[	O
43	O
],	O
we	O
anticipate	O
that	O
this	O
is	O
probably	O
due	O
to	O
the	O
fact	O
that	O
prior	O
to	O
treatment	O
,	O
WAPcre	O
;	O
Brca1F	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
female	O
mice	B-OG
contain	O
Brca1	B-GP
-	O
deficient	O
mammary	O
epithelial	O
cells	O
.	O

Also	O
,	O
because	O
Brca	B-GP
-/-	O
mouse	B-OG
embryonic	O
stem	O
cell	O
lines	O
are	O
5	O
-	O
fold	O
more	O
sensitive	O
to	O
cisplatin	O
than	O
Brca	B-GP
+/+	O
wild	O
type	O
cells	O
[	O
11	O
],	O
it	O
is	O
likely	O
that	O
Brca1	B-GP
loss	O
underpins	O
the	O
observed	O
sensitivity	O
to	O
cisplatin	O
.	O

Although	O
rapid	O
systemic	O
distribution	O
of	O
platinum	O
drugs	O
is	O
evident	O
after	O
ID	O
treatment	O
(	O
our	O
data	O
and	O
[	O
41	O
]),	O
we	O
also	O
showed	O
that	O
platinum	O
levels	O
in	O
the	O
circulation	O
and	O
untreated	O
glands	O
were	O
lower	O
than	O
can	O
be	O
expected	O
after	O
systemic	O
treatment	O
[	O
44	O
].	O

A	O
study	O
using	O
intra	O
tumor	B-DS
(	O
IT	O
)	O
injection	O
of	O
cisplatin	O
and	O
found	O
a	O
comparable	O
AUC	O
to	O
the	O
value	O
we	O
found	O
after	O
ID	O
injection	O
.	O

Compared	O
to	O
IP	O
injection	O
,	O
IT	O
administration	O
led	O
to	O
lower	O
plasma	O
concentrations	O
.	O

Systemic	O
exposure	O
to	O
platinum	O
after	O
IT	O
injection	O
was	O
calculated	O
to	O
be	O
65	O
-	O
75	O
%	O
of	O
the	O
exposure	O
after	O
systemic	O
administration	O
.	O

Since	O
IT	O
and	O
ID	O
cisplatin	O
administration	O
showed	O
a	O
similar	O
pharmacokinetic	O
profile	O
,	O
we	O
expect	O
that	O
also	O
ID	O
cisplatin	O
will	O
lead	O
to	O
lower	O
systemic	O
platinum	O
levels	O
compared	O
to	O
systemic	O
treatment	O
[	O
44	O
].	O

Our	O
findings	O
are	O
in	O
agreement	O
with	O
studies	O
showing	O
that	O
ID	O
treatment	O
with	O
other	O
chemotherapeutics	O
also	O
leads	O
to	O
systemic	O
exposure	O
[	O
39	O
,	O
40	O
].	O

Long	O
-	O
term	O
carcinogenicity	O
is	O
a	O
major	O
point	O
of	O
concern	O
in	O
prophylactic	O
treatments	O
using	O
chemotherapeutics	O
.	O

The	O
same	O
cytotoxic	O
agent	O
can	O
be	O
used	O
to	O
treat	O
cancer	B-DS
,	O
but	O
can	O
also	O
drive	O
carcinogenesis	O
[	O
47	O
].	O

ID	O
PLD	O
is	O
reported	O
to	O
induce	O
malignant	O
mammary	O
gland	O
tumors	B-DS
in	O
wild	O
type	O
mice	B-OG
after	O
a	O
follow	O
-	O
up	O
of	O
42	O
weeks	O
[	O
48	O
].	O

When	O
MMECs	O
were	O
isolated	O
from	O
mice	B-OG
treated	O
with	O
ID	O
PLD	O
,	O
recipients	O
developed	O
tumors	B-DS
[	O
48	O
].	O

Our	O
current	O
study	O
shows	O
that	O
cisplatin	O
leads	O
to	O
tumor	B-DS
formation	O
in	O
6	O
.	O
3	O
%	O
of	O
treated	O
mammary	O
glands	O
more	O
than	O
95	O
weeks	O
post	O
treatment	O
.	O

The	O
induction	O
of	O
late	O
tumors	B-DS
also	O
affected	O
overall	O
survival	O
after	O
cisplatin	O
treatment	O
.	O

The	O
induction	O
of	O
secondary	O
malignancies	O
may	O
be	O
explained	O
by	O
platinum	O
release	O
from	O
regenerating	O
tissue	O
leading	O
to	O
circulating	O
plasma	O
platinum	O
levels	O
up	O
to	O
20	O
years	O
after	O
treatment	O
[	O
49	O
,	O
50	O
].	O

Ovarian	B-DS
cancer	I-DS
survivors	O
show	O
an	O
increased	O
breast	B-DS
cancer	I-DS
risk	O
,	O
however	O
the	O
influence	O
of	O
chemotherapy	O
was	O
either	O
not	O
investigated	O
or	O
not	O
convincingly	O
shown	O
[	O
51	O
,	O
52	O
].	O

Genetic	O
and	O
reproductive	O
factors	O
predisposing	O
to	O
ovarian	B-DS
cancer	I-DS
may	O
also	O
have	O
contributed	O
to	O
breast	B-DS
cancer	I-DS
development	O
[	O
52	O
].	O

In	O
contrast	O
to	O
our	O
findings	O
in	O
mice	B-OG
,	O
it	O
was	O
shown	O
that	O
long	O
-	O
term	O
testicular	O
and	O
ovarian	B-DS
cancer	I-DS
survivors	O
have	O
no	O
increased	O
lung	B-DS
cancer	I-DS
risk	O
[	O
51	O
-	O
53	O
],	O
and	O
testicular	B-DS
cancer	I-DS
patients	O
treated	O
with	O
chemotherapy	O
only	O
do	O
not	O
develop	O
more	O
lung	B-DS
tumors	I-DS
during	O
follow	O
-	O
up	O
[	O
54	O
].	O

Despite	O
the	O
obvious	O
species	O
differences	O
in	O
rodents	B-OG
and	O
humans	B-OG
that	O
may	O
underlie	O
the	O
long	O
-	O
term	O
tumor	B-DS
formation	O
after	O
intraductal	O
cisplatin	O
in	O
our	O
used	O
preclinical	O
models	O
,	O
we	O
think	O
that	O
ID	O
administration	O
of	O
solvable	O
cisplatin	O
cannot	O
upfront	O
be	O
regarded	O
as	O
a	O
safe	O
alternative	O
to	O
prevent	O
BRCA	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
in	O
genetic	O
carriers	O
.	O

Possible	O
alternative	O
ways	O
of	O
delivering	O
an	O
immobilized	O
yet	O
locally	O
active	O
chemotherapy	O
should	O
be	O
developed	O
to	O
prevent	O
systemic	O
exposure	O
.	O

Since	O
intraductal	O
PLD	O
also	O
induced	O
mammary	B-DS
tumors	I-DS
,	O
we	O
feel	O
that	O
this	O
precludes	O
the	O
use	O
of	O
ID	O
chemotherapy	O
in	O
general	O
for	O
preventive	O
purposes	O
.	O

Using	O
local	O
therapy	O
intraductally	O
however	O
seems	O
to	O
be	O
feasible	O
and	O
effective	O
and	O
could	O
be	O
combined	O
with	O
the	O
use	O
of	O
nanocarriers	O
[	O
55	O
],	O
liposomes	O
[	O
56	O
],	O
or	O
antidotes	O
[	O
57	O
].	O

Olaparib	O
was	O
already	O
shown	O
to	O
be	O
effective	O
in	O
breast	B-DS
cancer	I-DS
treatment	O
[	O
17	O
-	O
21	O
,	O
23	O
,	O
24	O
],	O
but	O
now	O
we	O
also	O
demonstrate	O
the	O
prophylactic	O
effect	O
of	O
systemic	O
PARP	B-GP
-	O
inhibition	O
in	O
Brca1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
.	O

Combining	O
ID	O
cisplatin	O
and	O
olaparib	O
led	O
to	O
an	O
additional	O
effect	O
in	O
breast	B-DS
tumor	I-DS
incidence	O
compared	O
to	O
both	O
monotherapies	O
without	O
increasing	O
toxicity	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
investigate	O
the	O
optimal	O
dosages	O
of	O
combination	O
treatment	O
and	O
the	O
long	O
-	O
term	O
safety	O
of	O
olaparib	O
treatment	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
although	O
ID	O
treatment	O
using	O
cisplatin	O
,	O
especially	O
in	O
combination	O
with	O
PARP	B-GP
-	O
inhibition	O
successfully	O
attenuates	O
tumor	B-DS
formation	O
in	O
a	O
clinically	O
relevant	O
mouse	B-OG
model	O
of	O
BRCA1	B-GP
-	O
associated	O
breast	B-DS
cancer	I-DS
,	O
it	O
leads	O
to	O
long	O
-	O
term	O
local	O
and	O
systemic	O
secondary	O
malignancies	O
in	O
mice	B-OG
and	O
may	O
not	O
be	O
safe	O
in	O
humans	B-OG
.	O

MATERIALS	O
AND	O
METHODS	O

Mice	B-OG

F1	O
Wild	O
type	O
mice	B-OG
were	O
derived	O
from	O
crossings	O
between	O
FVB	O
/	O
NCrl	O
(	O
Charles	O
River	O
)	O
and	O
129P2	O
/	O
OlaHsd	O
(	O
Harlan	O
).	O
WAPcre	O
;	O
BrcaF	O
/	O
F	O
;	O
Trp53F	O
/	O
F	O
mice	B-OG
were	O
generated	O
by	O
crossing	O
Brca1F	O
/	O
F	O
conditional	O
female	O
mice	B-OG
[	O
58	O
]	O
with	O
male	O
WAPcre	O
;	O
Trp53F	O
/	O
F	O
mice	B-OG
[	O
43	O
].	O

Female	O
mice	B-OG
in	O
a	O
model	O
using	O
WAPCre	O
as	O
a	O
promoter	O
,	O
develop	O
mammary	B-DS
tumors	I-DS
for	O
which	O
the	O
onset	O
,	O
incidence	O
and	O
metastasis	O
are	O
pregnancy	O
and	O
lactation	O
-	O
independent	O
[	O
43	O
].	O

Genotyping	O
and	O
deletion	O
status	O
of	O
the	O
Trp53F	B-GP
,	O
Trp53Δ	O
,	O
Brca1F	B-GP
,	O
Brca1Δ	O
and	O
WAPcre	O
alleles	O
was	O
done	O
as	O
described	O
[	O
43	O
,	O
58	O
].	O

Onset	O
of	O
tumor	B-DS
growth	O
was	O
monitored	O
twice	O
weekly	O
from	O
the	O
age	O
of	O
4	O
months	O
onward	O
.	O

Mammary	B-DS
tumor	I-DS
volume	O
was	O
determined	O
by	O
caliper	O
measurements	O
using	O
the	O
following	O
formula	O
:	O
4	O
/	O
3	O
*((	O
3	O
.	O
14	O
)*((	O
length	O
+	O
width	O
)/	O
4	O
)^	O
3	O
).	O

Animals	B-OG
were	O
euthanized	O
if	O
mammary	B-DS
tumors	I-DS
reached	O
a	O
size	O
of	O
1000	O
mm3	O
or	O
in	O
case	O
of	O
severe	O
discomfort	O
otherwise	O
.	O

Animals	B-OG
were	O
scored	O
as	O
having	O
a	O
tumor	B-DS
when	O
there	O
was	O
a	O
tumor	B-DS
palpable	O
or	O
based	O
on	O
post	O
mortem	O
histological	O
assessment	O
.	O

Tumor	B-DS
-	O
free	O
latency	O
was	O
calculated	O
as	O
the	O
number	O
of	O
days	O
after	O
the	O
second	O
ID	O
injection	O
.	O

All	O
animal	B-OG
experiments	O
were	O
performed	O
according	O
to	O
institutional	O
guidelines	O
and	O
national	O
regulations	O
(	O
DEC2010	O
.	O
III	O
.	O
08	O
.	O
102	O
,	O
2011	O
.	O
III	O
.	O
04	O
.	O
050	O
,	O
2012	O
.	O
III	O
.	O
01	O
.	O
005	O
,	O
2012	O
.	O
III	O
.	O
09	O
.	O
086	O
).	O

Drugs	O

Cisplatin	O
(	O
1	O
mg	O
/	O
mL	O
in	O
saline	O
,	O
Pharmachemie	O
B	O
.	O
V	O
.)	O
was	O
administered	O
ID	O
in	O
a	O
total	O
volume	O
of	O
50	O
μl	O
per	O
mammary	O
gland	O
.	O

To	O
visualize	O
extravasation	O
or	O
incorrect	O
injection	O
,	O
cisplatin	O
or	O
control	O
was	O
mixed	O
with	O
0	O
.	O
05	O
%	O
methylene	O
blue	O
.	O

Olaparib	O
was	O
synthesized	O
by	O
Syncom	O
with	O
a	O
purity	O
of	O
more	O
than	O
99	O
%	O
by	O
HPLC	O
.	O

Olaparib	O
was	O
used	O
by	O
diluting	O
50	O
mg	O
/	O
ml	O
stocks	O
in	O
DMSO	O
with	O
10	O
%	O
2	O
-	O
hydroxyl	O
-	O
propyl	O
-	O
β	O
-	O
cyclodextrine	O
/	O
PBS	O
such	O
that	O
the	O
final	O
volume	O
administered	O
intraperitoneally	O
(	O
IP	O
)	O
was	O
10	O
μL	O
/	O
g	O
of	O
body	O
weight	O
.	O

Saline	O
0	O
.	O
9	O
%	O
(	O
Fresenius	O
Kabi	O
)	O
was	O
used	O
as	O
control	O
.	O

Intraductal	O
injection	O

Mice	B-OG
were	O
anesthetized	O
by	O
isoflurane	O
and	O
100	O
μl	O
(	O
0	O
.	O
03	O
mg	O
/	O
ml	O
)	O
Temgesic	O
(	O
buprenorphine	O
)	O
was	O
injected	O
subcutaneously	O
(	O
SC	O
)	O
as	O
analgesic	O
treatment	O
.	O

Mammary	O
ducts	O
were	O
cannulated	O
using	O
a	O
1	O
.	O
0	O
-	O
cm	O
,	O
33G	O
,	O
blunt	O
-	O
ended	O
needle	O
(	O
Hamilton	O
,	O
66780305	O
)	O
attached	O
to	O
a	O
50	O
μl	O
glass	O
syringe	O
(	O
Hamilton	O
66765501	O
).	O

Drugs	O
or	O
control	O
were	O
injected	O
into	O
the	O
mammary	O
gland	O
while	O
visualizing	O
the	O
nipple	O
opening	O
under	O
a	O
dissection	O
microscope	O
[	O
39	O
].	O

Orthotopic	O
transplantation	O
MMECs	O

Primary	O
mouse	B-OG
mammary	O
epithelium	O
cells	O
(	O
MMECs	O
)	O
were	O
obtained	O
from	O
mammary	O
glands	O
after	O
removal	O
of	O
the	O
intra	O
-	O
mammary	O
lymph	O
nodes	O
.	O

Tissue	O
was	O
finely	O
chopped	O
three	O
times	O
using	O
a	O
McIlwain	O
tissue	O
chopper	O
(	O
The	O
Mickle	O
Laboratory	O
Engineering	O
Co	O
.)	O
and	O
digested	O
for	O
1	O
hr	O
at	O
37	O
°	O
C	O
in	O
serum	O
-	O
free	O
DMEM	O
-	O
F12	O
medium	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
containing	O
0	O
.	O
1	O
mg	O
/	O
ml	O
porcine	O
pancreatic	O
trypsin	B-GP
(	O
Gibco	O
)	O
and	O
0	O
.	O
2	O
mg	O
/	O
ml	O
collagenase	B-GP
A	I-GP
(	O
Roche	O
).	O

Cells	O
were	O
washed	O
and	O
fibroblasts	O
were	O
allowed	O
to	O
adhere	O
for	O
1	O
hr	O
at	O
37	O
°	O
C	O
.	O

Non	O
-	O
adherent	O
epithelial	O
cells	O
were	O
collected	O
,	O
washed	O
,	O
pelleted	O
in	O
40	O
μl	O
serum	O
-	O
free	O
DMEM	O
-	O
F12	O
and	O
kept	O
on	O
ice	O
until	O
transplantation	O
.	O

MMECs	O
were	O
transplanted	O
in	O
3	O
-	O
week	O
-	O
old	O
wild	O
type	O
syngeneic	O
female	O
recipient	O
mice	B-OG
.	O

Recipient	O
mice	B-OG
were	O
anesthetized	O
by	O
isoflurane	O
.	O

Temgesic	O
(	O
buprenorphine	O
;	O
100	O
μl	O
(	O
0	O
.	O
03	O
mg	O
/	O
ml	O
))	O
was	O
injected	O
SC	O
as	O
analgesic	O
treatment	O
.	O

The	O
fourth	O
(	O
inguinal	O
)	O
mammary	O
gland	O
was	O
exposed	O
and	O
endogenous	O
mammary	O
epithelial	O
tissue	O
was	O
removed	O
.	O

Next	O
,	O
MMECs	O
were	O
injected	O
in	O
the	O
cleared	O
fat	O
pad	O
using	O
a	O
50	O
μl	O
Hamilton	O
syringe	O
,	O
after	O
which	O
the	O
animals	B-OG
were	O
sutured	O
.	O

Whole	O
mount	O
analysis	O
was	O
performed	O
8	O
weeks	O
after	O
transplantation	O
.	O

FACS	O
analysis	O

After	O
enzymatic	O
digestion	O
of	O
the	O
mammary	O
tissue	O
,	O
cells	O
were	O
incubated	O
with	O
red	O
blood	O
cell	O
lysis	O
buffer	O
(	O
8	O
.	O
26	O
g	O
NH4Cl	O
,	O
1	O
g	O
NaHCO3	O
,	O
0	O
.	O
0378	O
g	O
EDTA	O
in	O
1	O
L	O
dH20	O
)	O
to	O
remove	O
erythrocytes	O
(	O
15	O
minutes	O
).	O

Cells	O
were	O
washed	O
and	O
fibroblasts	O
were	O
allowed	O
to	O
adhere	O
for	O
1	O
hr	O
at	O
37	O
°	O
C	O
.	O

Non	O
-	O
adherent	O
epithelial	O
cells	O
were	O
collected	O
,	O
washed	O
in	O
0	O
.	O
02	O
%	O
EDTA	O
-	O
PBS	O
solution	O
,	O
pelleted	O
and	O
resuspended	O
in	O
0	O
.	O
25	O
%	O
w	O
/	O
v	O
trypsin	B-GP
/	O
0	O
.	O
2	O
%	O
w	O
/	O
v	O
EDTA	O
in	O
PBS	O
for	O
incubation	O
at	O
37	O
°	O
C	O
for	O
2	O
minutes	O
.	O

Cells	O
were	O
dissociated	O
through	O
a	O
70	O
μm	O
cell	O
strainer	O
and	O
resuspended	O
in	O
fresh	O
RPMI	O
/	O
10	O
%	O
FCS	O
for	O
quantification	O
.	O

Cells	O
were	O
incubated	O
with	O
primary	O
antibodies	B-GP
for	O
45	O
minutes	O
on	O
ice	O
(	O
FITC	O
-	O
conjugated	O
anti	O
-	O
CD24	B-GP
(	O
clone	O
M1	O
/	O
69	O
,	O
BD	O
Biosciences	O
,	O
0	O
.	O
5	O
μg	O
/	O
ml	O
),	O
PE	B-GP
-	O
Cy5	O
-	O
conjugated	O
anti	O
-	O
CD45	B-GP
(	O
clone	O
30	O
-	O
F11	O
,	O
BD	O
Biosciences	O
,	O
0	O
.	O
25	O
μg	O
/	O
ml	O
),	O
and	O
PE	B-GP
-	O
conjugated	O
anti	O
-	O
Sca	B-GP
-	I-GP
1	I-GP
(	O
clone	O
D7	O
,	O
0	O
.	O
5	O
μg	O
/	O
ml	O
;	O
BD	O
Biosciences	O
,	O
0	O
.	O
5	O
μg	O
/	O
ml	O
)).	O

Before	O
FACS	O
analysis	O
,	O
cells	O
were	O
incubated	O
with	O
0	O
.	O
01	O
%	O
4	O
’,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
dihydrochloride	O
(	O
DAPI	O
)	O
for	O
15	O
minutes	O
.	O

Analyses	O
were	O
carried	O
out	O
on	O
a	O
BD	O
FACSVantageSE	O
DiVa	O
(	O
BD	O
Biosciences	O
)	O
and	O
gating	O
was	O
performed	O
as	O
described	O
[	O
59	O
].	O

Flow	O
Jo	O
software	O
version	O
10	O
was	O
used	O
for	O
analysis	O
.	O

Whole	O
mount	O
analysis	O

Mammary	O
glands	O
were	O
dissected	O
and	O
stretched	O
on	O
a	O
glass	O
slide	O
.	O

Glands	O
were	O
fixed	O
in	O
a	O
mixture	O
of	O
methanol	O
:	O
1	O
,	O
1	O
,	O
1	O
-	O
trichloroethane	O
:	O
acetic	O
acid	O
(	O
6	O
:	O
3	O
:	O
1	O
)	O
for	O
4	O
hours	O
and	O
stained	O
overnight	O
with	O
carmine	O
aluminium	O
staining	O
solution	O
(	O
2	O
g	O
/	O
l	O
carmine	O
,	O
5	O
g	O
/	O
l	O
aluminium	O
potassium	O
sulphate	O
dissolved	O
in	O
water	O
).	O

After	O
stepwise	O
dehydration	O
in	O
70	O
%,	O
95	O
%	O
and	O
100	O
%	O
ethanol	O
,	O
glands	O
were	O
cleared	O
in	O
xylene	O
for	O
10	O
minutes	O
and	O
photographs	O
were	O
taken	O
with	O
a	O
Zeiss	O
Stemi	O
2000	O
-	O
C	O
stereo	O
microscope	O
.	O

We	O
defined	O
effect	O
size	O
as	O
follows	O
:	O
total	O
effect	O
(	O
0	O
%	O
outgrowth	O
),	O
subtotal	O
(	O
up	O
to	O
25	O
%	O
outgrowth	O
),	O
partial	O
(	O
more	O
than	O
25	O
%	O
outgrowth	O
),	O
and	O
no	O
effect	O
(	O
100	O
%	O
outgrowth	O
).	O

Histological	O
analysis	O

Tissues	O
were	O
isolated	O
and	O
fixed	O
in	O
4	O
%	O
formaldehyde	O
.	O

Tissues	O
were	O
dehydrated	O
,	O
cut	O
into	O
4	O
μm	O
sections	O
,	O
and	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O

For	O
immunohistochemical	O
stainings	O
,	O
fixed	O
sections	O
were	O
rehydrated	O
and	O
incubated	O
with	O
primary	O
antibodies	B-GP
against	O
β	B-GP
-	I-GP
casein	I-GP
(	O
Santa	O
-	O
Cruz	O
SC	O
-	O
30042	O
,	O
FL	O
-	O
231	O
,	O
rabbit	B-OG
,	O
1	O
:	O
100	O
)	O
and	O
cleaved	O
caspase	B-GP
3	I-GP
(	O
Cell	O
Signaling	O
9661	O
,	O
rabbit	B-OG
,	O
1	O
:	O
500	O
).	O

Endogenous	O
peroxidases	B-GP
were	O
blocked	O
with	O
3	O
%	O
H2O2	O
and	O
biotin	O
-	O
conjugated	O
secondary	O
antibodies	B-GP
were	O
used	O
,	O
followed	O
by	O
incubation	O
with	O
HRP	B-GP
-	O
conjugated	O
streptavidin	B-GP
-	O
biotin	O
complex	O
(	O
DAKO	O
).	O

Substrate	O
was	O
developed	O
with	O
DAB	O
(	O
DAKO	O
)	O
and	O
pictures	O
were	O
made	O
using	O
a	O
Nikon	O
Eclipse	O
E800	O
with	O
a	O
Nikon	O
digital	O
camera	O
DXM1200	O
.	O

Appropriate	O
positive	O
and	O
negative	O
controls	O
were	O
used	O
throughout	O
.	O

Pharmacokinetic	O
analysis	O

Mice	B-OG
were	O
euthanized	O
at	O
5	O
minutes	O
,	O
15	O
minutes	O
,	O
30	O
minutes	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
hour	O
intervals	O
after	O
ID	O
injection	O
.	O

Blood	O
was	O
collected	O
via	O
cardiac	O
puncture	O
and	O
tissue	O
was	O
isolated	O
and	O
frozen	O
.	O

Platinum	O
concentrations	O
were	O
measured	O
by	O
a	O
validated	O
Inductively	O
Coupled	O
Plasma	O
Mass	O
Spectrometry	O
(	O
ICPMS	O
)	O
method	O
as	O
described	O
by	O
Brouwers	O
et	O
al	O
.	O
[	O
60	O
].	O

Statistical	O
analysis	O

For	O
statistical	O
analyses	O
IBM	O
SPSS	O
Statistics	O
Version	O
20	O
was	O
used	O
.	O

For	O
dichotomous	O
variables	O
Chi	O
square	O
tests	O
were	O
used	O
;	O
for	O
continuous	O
variables	O
t	O
-	O
test	O
(	O
normal	O
distribution	O
),	O
Mann	O
Whitney	O
test	O
(	O
no	O
normal	O
distribution	O
,	O
no	O
paired	O
data	O
)	O
or	O
Wilcoxon	O
signed	O
rank	O
test	O
(	O
no	O
normal	O
distribution	O
,	O
paired	O
data	O
).	O

For	O
survival	O
analysis	O
Kaplan	O
-	O
Meier	O
curves	O
and	O
Log	O
-	O
rank	O
(	O
Mantel	O
-	O
Cox	O
)	O
tests	O
were	O
performed	O
.	O

A	O
two	O
-	O
sided	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

SUPPLEMENTARY	O
MATERIALS	O
FIGURES	O
AND	O
TABLES	O

Author	O
contributions	O

JSG	O
,	O
PJD	O
,	O
JHB	O
,	O
JJ	O
,	O
EW	O
and	O
PWBD	O
conceived	O
study	O
design	O
.	O

JSG	O
,	O
PJD	O
,	O
MA	O
,	O
EJV	O
,	O
XP	O
,	O
NDH	O
,	O
and	O
HR	O
carried	O
out	O
experiments	O
.	O

JSG	O
,	O
PJD	O
,	O
HR	O
,	O
SAY	O
,	O
AB	O
and	O
PWBD	O
analyzed	O
data	O
.	O

All	O
authors	O
were	O
involved	O
in	O
writing	O
the	O
paper	O
and	O
had	O
final	O
approval	O
of	O
the	O
submitted	O
and	O
published	O
versions	O
.	O

CONFLICTS	O
OF	O
INTEREST	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

